AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23257314
Drug: 3-mg po
RxNorm normalized name: lusutrombopag 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-mg po mibampator
Trial: 22001199
Drug: 1,200 mg
RxNorm normalized name: lecithin 1,200 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,200 mg glucosamine sulfate
Trial: 15851238
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors (ANGI)
Trial: 15851238
Drug: No angiotensin
RxNorm normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors (ANGI)
Trial: 15851238
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors (ANGI) in patients with congestive heart failure or impaired left ventricular function
Trial: 2752739
Drug: Commercial cream
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercial cream containing 6% purified lanolin
Trial: 1157005
Drug: 6-mercaptopurine (6MP)
RxNorm normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6-mercaptopurine (6MP) (75 mg/m2/day)
Trial: 1157005
Drug: methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: methotrexate (MTX) (25 mg/m2/twice weekly)
Trial: 1157005
Drug: cyclophosphamide (CYC)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cyclophosphamide (CYC) (100 mg/m2/day)
Trial: 21741088
Drug: Concurrent immunomodulator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent immunomodulator use (purine antimetabolites or methotrexate)
Trial: 21741088
Drug: Development of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Development of antibodies to infliximab (ATIs)
Trial: 17645255
Drug: Simple oral
RxNorm normalized name: Simple Oral Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple oral administration of Wenlafaxin
Trial: 11355435
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment using local points ST‐6, ST‐7, SI‐18, GV‐20, GB‐20, BL‐10 and distant point LI‐4, with needles manipulated to achieve De‐qui sensation and left in situ for 30 min, administered weekly for a total of six treatments.
Trial: 9663368
Drug: Enalapril 5
RxNorm normalized name: enalapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 5 mg-felodipine ER 2.5 mg once daily, titrated to a maximum of enalapril 10 mg-felodipine ER 10 mg if SiDBP not controlled after 4 weeks; Hydrochlorothiazide (HCTZ) 12.5 mg added if hypertension not controlled at maximum dose.
Trial: 9663368
Drug: Enalapril-felodipine ER
RxNorm normalized name: enalapril / felodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril-felodipine ER combination with HCTZ 12.5 mg
Trial: 2571216
Drug: CGP 17582
RxNorm normalized name: Leucoflex CGP KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGP 17582 B (50 mg orally)
Trial: 2571216
Drug: Propranolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (10 mg orally)
Trial: 28644774
Drug: Gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Gemtuzumab ozogamicin (GO) with chemotherapy (two doses of GO during induction and intensification)
Trial: 28644774
Drug: Standard five-course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard five-course chemotherapy alone (No-GO arm)
Trial: 28644774
Drug: Gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Gemtuzumab ozogamicin (GO) with chemotherapy
Trial: 26196193
Drug: ECMO ±
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECMO ± smoke inhalation acute lung injury (SALI)
Trial: 17063425
Drug: Systemic bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Systemic bevacizumab (5 mg/kg), administered three times at 2-week intervals.
Trial: 17063425
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab (1 mg), administered up to three times at 4-week intervals.
Trial: 10320603
Drug: Patient Controlled
RxNorm normalized name: PATIENT CONTROLLED ANALGESIA VIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient Controlled Analgesia (PCA) with background infusion (BI) at 15 microg x kg(‐1) x h(‐1) and bolus doses of 15 microg x kg(‐1) with a lock‐out interval of 10 min
Trial: 10320603
Drug: Continuous Infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Infusion (CI) at 20 to 40 microg x kg(‐1) x h(‐1)
Trial: 6412795
Drug: Metoprolol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (200 mg) plus Placebo
Trial: 6412795
Drug: Metoprolol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (200 mg) plus Chlorthalidone (25 mg)
Trial: 31808594
Drug: Ivermectin 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin 0.4 mg/kg, orally, once 2 hours before infection
Trial: 30153737
Drug: Comprehensive smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive smoking treatment including individual counseling, free pharmacotherapy (dual nicotine replacement therapy or varenicline), and 5 weeks of contingency management.
Trial: 30153737
Drug: Delayed intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed intervention control sites (no treatment during the study period).
Trial: 16611273
Drug: Infliximab 5
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab 5 mg/kg maintenance every 8 weeks
Trial: 8869676
Drug: Esmolol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol infusion (mean rate 330 +/- 10 micrograms/kg/min)
Trial: 1531487
Drug: All therapies
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All therapies (including manual therapy, physiotherapy, GP treatment, and placebo)
Trial: 6845352
Drug: Propranolol 160
RxNorm normalized name: propranolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 160 mg (divided doses)
Trial: 6845352
Drug: Ethanol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (50 ml/70 kg body weight)
Trial: 31810456
Drug: Free paracetamol
RxNorm normalized name: Soul Pattinson Colour Free Paracetamol Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free paracetamol distribution (experimental arm)
Trial: 27442691
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus contingency management (STCM)
Trial: 27442691
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment alone (STA)
Trial: 25196301
Drug: Synbiotic bread
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synbiotic bread (Lactobacillus sporogenes 1 × 10(8) CFU, 0.07 g inulin per 1 g)
Trial: 22615088
Drug: Medication reconciliation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication reconciliation phone call from a medical resident within 72 hours after discharge
Trial: 12011970
Drug: HR (Paroven,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HR (Paroven, Venoruton; 0‐(beta‐hydroxyethyl)‐rutosides), 1g sachets, twice daily, for 4 weeks
Trial: 2319479
Drug: Caffeine 56
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine 56 mg
Trial: 2319479
Drug: Caffeine 18
RxNorm normalized name: Acetaminophen/Aspirin/Caffeine 180 MG-230 MG-15 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 18 mg
Trial: 2319479
Drug: Caffeine 10
RxNorm normalized name: caffeine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 10 mg
Trial: 377152
Drug: 2g metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2g metronidazole rectal suppositories
Trial: 31787562
Drug: ω‐3 PUFAs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω‐3 PUFAs (2 g twice daily)
Trial: 31787562
Drug: ω‐3 PUFAs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω‐3 PUFAs + NX (220 mg twice daily)
Trial: 31787562
Drug: NX (220 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NX (220 mg twice daily)
Trial: 21068692
Drug: Separate Hib-TT
RxNorm normalized name: TT 173
DrugBank: TT 173 (DB17717)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate Hib-TT and MenC-CRM197 vaccines
Trial: 11704315
Drug: 200 mg/m(2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/m(2) amifostine i.v. 30 min before radiation
Trial: 9033316
Drug: Heparin-coated cardiopulmonary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated cardiopulmonary bypass circuit
Trial: 8345794
Drug: Oral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral therapy (conjugated equine estrogens, 0.625 mg/d continuous + levonorgestrel, 0.075 mg/d for 12 days of each 28‐day cycle)
Trial: 8345794
Drug: Transdermal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal therapy (estradiol 17 beta, 0.05 mg/d continuous + norethindrone acetate, 0.25 mg/d for 14 days of each 28‐day cycle)
Trial: 27855699
Drug: Prolonged Exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged Exposure Treatment for Adolescents (PE-A)
Trial: 25885496
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 4 mL/kg (group L)
Trial: 25885496
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 10 mL/kg (group H)
Trial: 20685760
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group maintained usual daily activity level
Trial: 10530408
Drug: T-cell receptor
RxNorm normalized name: T-cell receptor marker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-cell receptor (TCR) gene rearrangements using primers hybridising to TCR delta and gamma genes
Trial: 10530408
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of all five primer sets
Trial: 29920211
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (rs6720173‐GG, rs3808607‐G, and rs760241‐A genotypes)
Trial: 24401211
Drug: Omega-3 PUFAs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 PUFAs (2 g/day for 12 weeks)
Trial: 22206609
Drug: Low-tube voltage
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-tube voltage (80 kVp) 320-detector row volume CT angiography (L-VCTA)
Trial: 11811169
Drug: i.v. CRF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. CRF as a 1.0-microg/kg bolus followed by a constant infusion (1.0 microg/kg/h)
Trial: 2405994
Drug: Transurethral debulking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transurethral debulking surgery combined with upfront CMV chemotherapy plus cisplatin and 4000 cGy
Trial: 2405994
Drug: Neoadjuvant MCV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant MCV chemotherapy for selective bladder preservation
Trial: 31147359
Drug: Morita Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morita Therapy (MT)
Trial: 27314331
Drug: Darmocare Pre(®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darmocare Pre(®) (prebiotic formulation)
Trial: 25825102
Drug: 8% lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8% lignocaine gel
Trial: 25825102
Drug: 15% lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15% lignocaine spray
Trial: 21932114
Drug: Monthly minodronate
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly minodronate at 30 mg
Trial: 21932114
Drug: Monthly minodronate
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly minodronate at 50 mg
Trial: 21932114
Drug: Daily minodronate
RxNorm normalized name: Minodronic acid
DrugBank: Minodronic acid (DB06548)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Daily minodronate at 1 mg
Trial: 21932114
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (30 mg, 50 mg, and 1 mg daily)
Trial: 19188545
Drug: Gemcitabine-based chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine-based chemotherapy (gemcitabine plus carboplatin, paclitaxel, or cisplatin)
Trial: 11725940
Drug: Daily records
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily records of physical activity (intervention group)
Trial: 9164824
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg Ca as AAACa after each meal and 450 mg at bedtime
Trial: 9164824
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg after each meal
Trial: 3111280
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 35% CO2 and 65% O2; Duration: Not specified
Trial: 25880814
Drug: OXCAP-RT (oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OXCAP-RT (oxaliplatin 85 mg/m2 Day 1,15,29; capecitabine 625 mg/m2 twice daily on days of RT; RT-45 Gy/25 fractions/5 weeks)
Trial: 25880814
Drug: CarPac-RT (Carboplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CarPac-RT (Carboplatin AUC2 and paclitaxel 50 mg/m2 Day 1,8,15,22,29; RT-45 Gy/25 fractions/5 weeks)
Trial: 23674855
Drug: Nigella sativa
RxNorm normalized name: NIGELLA SATIVA SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nigella sativa (N. sativa) administered for three months at a dose of 450 mg three times daily
Trial: 21270583
Drug: Intradermal buffered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal buffered lidocaine
Trial: 21270583
Drug: Intradermal bacteriostatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal bacteriostatic normal saline
Trial: 19207871
Drug: Standard vaccination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard vaccination protocol: three doses of 40 microg i.m. at months 0, 1 and 6
Trial: 8602592
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate (CaCO3) 1000 mg/d
Trial: 8602592
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate (CaCO3) 1000 mg/d plus 5 micrograms (200 IU) vitamin D/d
Trial: 8602592
Drug: Milk (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk (1 L more than usual daily diet)
Trial: 8602592
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets (three tablets daily)
Trial: 20926016
Drug: Tamsulosin 0.4
RxNorm normalized name: tamsulosin 0.4 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.4 mg/day for 4 weeks
Trial: 20926016
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (non‐placebo, non‐treatment)
Trial: 19001742
Drug: FDP 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDP 200 mg/kg infused intravenously before anesthesia
Trial: 19001742
Drug: FDP 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDP 200 mg/kg
Trial: 16380703
Drug: Insulin-like Growth
RxNorm normalized name: Insulin-like growth factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-like Growth Factor-I (IGF-I)
Trial: 16380703
Drug: Insulin-like Growth
RxNorm normalized name: Insulin-like growth factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-like Growth Factor Binding Protein-3 (IGFBP-3)
Trial: 12417879
Drug: Albuterol MDI
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol MDI (0 to 576 microg)
Trial: 12417879
Drug: Albuterol MDI
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol MDI (90 microg and 180 microg)
Trial: 12417879
Drug: Albuterol MDI
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol MDI
Trial: 10599545
Drug: GnRH agonist/hMG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRH agonist/hMG
Trial: 7547766
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (0.625 mg conjugated equine oestrogens with 0.15 mg cyclic norgestrel for 12 days per 28 day cycle)
Trial: 1437059
Drug: Clotrimazole troches,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole troches, 10 mg, five times daily
Trial: 1437059
Drug: Nystatin suspension,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nystatin suspension, 500,000 units, four times daily
Trial: 3980803
Drug: Trimethylpsoralen bath
RxNorm normalized name: 4,8,5'-Trimethylpsoralen
DrugBank: Trioxsalen (DB04571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trimethylpsoralen bath plus ultraviolet A (bath PUVA) combined with oral retinoid, etretinate (1 mg/kg/day)
Trial: 3980803
Drug: Etretinate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etretinate (1 mg/kg/day)
Trial: 3980803
Drug: Bath PUVA
RxNorm normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bath PUVA (maintenance therapy)
Trial: 3980803
Drug: Etretinate (25‐50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etretinate (25‐50 mg daily)
Trial: 28228411
Drug: Dexamethasone implant
RxNorm normalized name: dexamethasone Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone implant (DEX)
Trial: 12764624
Drug: Metformin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin therapy (2x850 mg/day for 8 weeks)
Trial: 11527172
Drug: Inchin‐ko‐to (ICKT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inchin‐ko‐to (ICKT) 0.15 g/kg per day administered orally for 1 year
Trial: 7920930
Drug: Step-down protocol
RxNorm normalized name: Kool-Down
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Step-down protocol (FSH +/‐ hMG without LHRH agonist)
Trial: 7920930
Drug: Step-up protocol
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Step-up protocol (FSH +/‐ hMG without LHRH agonist)
Trial: 7920930
Drug: Step-down protocol
RxNorm normalized name: Kool-Down
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Step-down protocol (FSH +/‐ hMG with LHRH agonist)
Trial: 7920930
Drug: Step-up protocol
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Step-up protocol (FSH +/‐ hMG with LHRH agonist)
Trial: 3532967
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A (CyA) 5 mg/kg daily
Trial: 29407633
Drug: No anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anticoagulant (control)
Trial: 22747652
Drug: Perceived drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perceived drug treatment
Trial: 22747652
Drug: Perceived placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perceived placebo treatment
Trial: 15869544
Drug: Clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol propionate (0.05%) applied once daily
Trial: 15869544
Drug: Initial once-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial once-daily followed by alternate-day application
Trial: 28767570
Drug: Oxycodone hydrochloride
RxNorm normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone hydrochloride 5mg (5mL)
Trial: 28767570
Drug: Morphine hydrochloride
RxNorm normalized name: Morphine hydrochloride
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine hydrochloride 5mg (5mL)
Trial: 25702400
Drug: Allapinine (ALP)
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allapinine (ALP) (1.5 mg/kg/d)
Trial: 25702400
Drug: Quinidine bisulphate
RxNorm normalized name: quinidine bisulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine bisulphate (QUIN) (15 mg/kg/d)
Trial: 18922712
Drug: Multiple injections
RxNorm normalized name: sodium acetate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple injections of <0.5 ml 1% polidocanol foam